Posted by Michael Wonder on 26 Sep 2024
Pfizer Canada and BioNTech receive Health Canada approval of Omicron KP.2 variant adapted COVID-19 vaccine
24 September 2024 - Omicron KP.2 variant adapted vaccine Comirnaty is now authorised in Canada for individuals 6 months of age and older. It is expected to be available in Canada in the coming weeks.
The updated Comirnaty vaccine targets the Omicron KP.2 variant, one of the most recently circulating SARS-CoV-2 lineages.
